Dana-Farber Cancer Institute
Avatar

2022 Treatment Landscape and Future Directions of R/R Multiple Myeloma

By Dana-Farber Cancer Institute FEATURING Nikhil Munshi
February 2, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:18
Treatment Considerations in CLL: Challenging Patient Cases

Treatment Considerations for Ibrutinib-Intolerant Patients - A Patie…

Feat. M. Shadman

Featured Video

15:52
Lilly

BTK Inhibition for Patients with MCL: Safety and Efficacy Data

Feat. J. Pagel

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

07:11
GRACE

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

Feat. A. Goodman, A. Jeong, S. Rajeeve
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
12:38
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…

Feat. S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…

Feat. H. Hashmi
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
12:33
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…

Feat. K. Patel
13:18
Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak
07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
44:49
Dana-Farber Cancer Institute

Recent Updates in Multiple Myeloma

Feat. K. Anderson
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
32:52
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

The Improbable History of CAR T-Cells

Feat. C. June
05:22
PrecisCa

Teclistamab in R/R Multiple Myeloma: Results From the MajesTEC-1 Tri…

Feat. A. Nooka
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
18:27
Indy Hematology Review

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…

Feat. J. Mikhael
14:41
Sanofi

Efficacy and Safety of a Treatment Option for Adults with Multiple M…

Feat. J. Mikhael
15:08
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient

New Therapies for Relapsed Myeloma in 2023

Feat. D. Vogl
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky